Status:
COMPLETED
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
Lead Sponsor:
Bayer
Collaborating Sponsors:
Regeneron Pharmaceuticals
Conditions:
Wet Macular Degeneration
Eligibility:
All Genders
Brief Summary
The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting. In addition, the study will asc...
Eligibility Criteria
Inclusion
- Treatment-naïve eyes with neovascularization AMD, with the indication to be treated with Aflibercept. One and/or two eyes per patient.
Exclusion
- Eyes treated previously with another anti-VEGF drug.
Key Trial Info
Start Date :
September 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
2312 Patients enrolled
Trial Details
Trial ID
NCT03278262
Start Date
September 1 2017
End Date
December 31 2017
Last Update
October 29 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Lund, Sweden